Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathurin Fumery

Showing results (1-10 of 254) with videos related to

Pageof 26
Sort By:
United European Gastroenterology Journal|December 12, 2024
Modifying Our Environment to Improve Outcomes in Inflammatory Bowel Diseases?Mathurin Fumery, Nicolas Richard
The Lancet. Gastroenterology & Hepatology|December 17, 2023
Guselkumab in Crohn's disease: the IL-23 race continuesMathurin Fumery, Anthony Buisson
Alimentary Pharmacology & Therapeutics|April 14, 2025
Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease? Authors' ReplyNicolas Richard, Mathurin Fumery
Alimentary Pharmacology & Therapeutics|June 20, 2026
Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' ReplyNicolas Richard, Mathurin Fumery
The American Journal of Gastroenterology|September 7, 2017
Response to Dhoble et alMathurin Fumery, Matthieu Allez
Journal of Crohn'S & Colitis|May 27, 2021
Histological Scores in Inflammatory Bowel Disease: A New Kid in the BlockMathurin Fumery, Denis Chatelain
The Lancet. Gastroenterology & Hepatology|April 11, 2024
Has the time come for a systematic top-down approach in Crohn's disease?Mathurin Fumery, Anthony Buisson
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2021
ReplyClara Yzet, Mathurin Fumery
Alimentary Pharmacology & Therapeutics|May 27, 2023
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's replyMathurin Fumery, Xavier Roblin
Alimentary Pharmacology & Therapeutics|March 23, 2023
Editorial: risankizumab - ready to break ceilings? author's replyMathurin Fumery, Laurent Peyrin-Biroulet
Pageof 26

Showing results (1-10 of 254) with videos related to

Sort By:
Pageof 26
United European Gastroenterology Journal|December 12, 2024
Modifying Our Environment to Improve Outcomes in Inflammatory Bowel Diseases?Mathurin Fumery, Nicolas Richard
The Lancet. Gastroenterology & Hepatology|December 17, 2023
Guselkumab in Crohn's disease: the IL-23 race continuesMathurin Fumery, Anthony Buisson
Alimentary Pharmacology & Therapeutics|April 14, 2025
Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease? Authors' ReplyNicolas Richard, Mathurin Fumery
Alimentary Pharmacology & Therapeutics|June 20, 2026
Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' ReplyNicolas Richard, Mathurin Fumery
The American Journal of Gastroenterology|September 7, 2017
Response to Dhoble et alMathurin Fumery, Matthieu Allez
Journal of Crohn'S & Colitis|May 27, 2021
Histological Scores in Inflammatory Bowel Disease: A New Kid in the BlockMathurin Fumery, Denis Chatelain
The Lancet. Gastroenterology & Hepatology|April 11, 2024
Has the time come for a systematic top-down approach in Crohn's disease?Mathurin Fumery, Anthony Buisson
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2021
ReplyClara Yzet, Mathurin Fumery
Alimentary Pharmacology & Therapeutics|May 27, 2023
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's replyMathurin Fumery, Xavier Roblin
Alimentary Pharmacology & Therapeutics|March 23, 2023
Editorial: risankizumab - ready to break ceilings? author's replyMathurin Fumery, Laurent Peyrin-Biroulet
Pageof 26